Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

Rhea-AI Summary

Athenex (NASDAQ: ATNX) has announced a corporate and financial update for the third quarter of 2021, scheduled for November 4, 2021. The update will be accompanied by a conference call at 10:00 a.m. ET, allowing investors to engage with management. Participants can join via specific dialing numbers or through a live audio webcast available on the company’s Investor Relations website.

Athenex focuses on developing innovative cancer treatments and operates through three platforms aimed at enhancing drug commercial viability.

Positive

• Scheduled corporate and financial update indicates transparency and ongoing communication with investors.
• Utilizing multiple platforms (Oncology Innovation, Commercial, and Global Supply Chain) suggests a well-rounded approach to drug development.
• The conference call allows for direct engagement between management and shareholders, which can positively affect investor relations.

Negative

• None.

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex’s management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic: (855) 227-0567

International: (612) 979-9912

Passcode: 7292300

The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.

Athenex Contacts

Investors

Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com

Caileigh Dougherty
Athenex, Inc.
Email: cdougherty@athenex.com

FAQ

When is Athenex's third quarter 2021 financial update?

Athenex's third quarter 2021 financial update is scheduled for November 4, 2021.

What time will Athenex's conference call take place?

The conference call will take place at 10:00 a.m. Eastern Time.

How can I participate in Athenex's conference call?

Participants can join Athenex's conference call by dialing (855) 227-0567 for domestic calls or (612) 979-9912 for international calls.

Where can I find the audio webcast of Athenex's call?

The audio webcast can be accessed on Athenex's Investor Relations website.

What does Athenex focus on in its business operations?

Athenex focuses on discovering, developing, and commercializing novel therapies for cancer treatment.